Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $20.06 USD
Change Today +1.82 / 9.98%
Volume 1.9M
AEGR On Other Exchanges
As of 5:20 PM 07/28/15 All times are local (Market data is delayed by at least 15 minutes).

aegerion pharmaceuticals inc (AEGR) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/30/14 - $36.68
52 Week Low
07/6/15 - $16.68
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

aegerion pharmaceuticals inc (AEGR) Related Businessweek News

No Related Businessweek News Found

aegerion pharmaceuticals inc (AEGR) Details

Aegerion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapies for patients with debilitating rare diseases in the United States. The company’s products include JUXTAPID (lomitapide) capsules, an adjunct to a low-fat diet and other lipid-lowering treatments, including low-density lipoprotein, low-density lipoprotein cholesterol, total cholesterol, apolipoprotein B, and non-high-density lipoprotein cholesterol in adult patients with homozygous familial hypercholesterolemia (HoFH); and LOJUXTA (lomitapide) hard capsule used as a treatment for HoFH in adults. Its products also comprise MYALEPT (metreleptin), a recombinant analogue of human leptin, indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy. The company distributes its products directly to patients and other purchasers through a specialty pharmacy. Aegerion Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Cambridge, Massachusetts.

301 Employees
Last Reported Date: 05/8/15
Founded in 2005

aegerion pharmaceuticals inc (AEGR) Top Compensated Officers

Chief Medical Officer
Total Annual Compensation: $405.0K
Chief Performance Officer
Total Annual Compensation: $341.3K
Chief Regulatory Officer and Senior Vice Pres...
Total Annual Compensation: $320.0K
Compensation as of Fiscal Year 2014.

aegerion pharmaceuticals inc (AEGR) Key Developments

Aegerion Pharmaceuticals, Inc. Announces Management Changes

Aegerion Pharmaceuticals, Inc. announced that Aegerion board member Sandford Drexel Smith has been appointed interim Chief Executive Officer of the company. Marc Beer offered his resignation as CEO and member of the board, as did Craig Fraser as Chief Operating Officer, effective immediately. Mr. Smith will also assume Mr. Fraser's responsibilities on an interim basis. Mr. Smith has served as a director of the company since 2012 and was most recently Executive Vice President and President International Group for Genzyme Corporation, where he was a member of Genzyme's Executive Committee.

Aegerion Pharmaceuticals, Inc. Announces Management Changes

Aegerion Pharmaceuticals, Inc. announced the appointment of Gregory D. Perry as chief financial officer, effective July 6, 2015. Mr. Perry replaces David Aubuchon, interim chief financial officer, who will continue in his role as chief accounting officer of Aegerion. Gregory Perry most recently served as chief financial officer of Eleven Biotherapeutics.

Aegerion Pharmaceuticals, Inc. Announces Executive Appointments

Aegerion Pharmaceuticals, Inc. announced key new hires in the medical affairs and drug safety functions. Jerome Premmereur, MD, joins the company as Vice President, Global Head of Medical Affairs. Dr. Premmereur was previously senior safety leader at Novartis Vaccines. He has more than 20 years of experience in pharmaceutical development, the last 10 of which were dedicated to global medical affairs including in the areas of thrombosis, cardiology, metabolism and oncology. Sam Yonren, MD, joins the company as Vice President, Global Head of Drug Safety. Dr. Yonren previously led global pharmacovigilance at Seattle Genetics. He has managed product safety with regulators in North America, Europe and Japan, while overseeing post-marketing activities in various therapeutic areas.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AEGR:US $20.06 USD +1.82

AEGR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Isis Pharmaceuticals Inc $54.40 USD +0.72
View Industry Companies

Industry Analysis


Industry Average

Valuation AEGR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.7x
Price/Book 3.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AEGERION PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at